Table 1.

Range of rates (%) of ADAbs formation to biologics in patients with IBD^a,b.

Biologic agent	All studies (n)	CD (n)	UC (n)	CD or UC (n)
Infliximabc	0.0–65.3 (73)	2.9–60.8 (22)	6.1–41.0 (8)	0.0–65.3 (43)
Adalimumab	0.3–38.0 (22)	0.3–35.0 (11)	2.9–5.3 (3)	14.0–38.0 (8)
Certolizumab pegol	3.3–25.3 (4)	3.3–25.3 (4)	–	–
Vedolizumab	1.0–4.1 (4)	1.0–4.1 (2)	3.7 (1)	4.0 (1)
Golimumab	0.4–2.9 (2)	–	0.4–2.9 (2)	–
Ustekinumab	0.7 (1)	0.7 (1)	–	–

^aOnly studies reporting rates of ADAbs were included (eight studies did not report specific proportions of patients developing ADAbs).

^bImmunogenicity analyses are product- and assay-specific.

^cOne selected study was excluded from analysis as this had a small sample size (n = 28) and a high rate of immunogenicity (79%).

–, no publications available; ADAbs, anti-drug antibodies; CD, Crohn’s disease; n, number of studies; UC, ulcerative colitis.